BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 77,100 shares, a growth of 267.1% from the May 31st total of 21,000 shares. Based on an average daily volume of 128,700 shares, the days-to-cover ratio is currently 0.6 days. Approximately 6.0% of the shares of the company are short sold.

BioCardia Trading Up 3.8 %

Shares of BioCardia stock traded up $0.11 on Thursday, reaching $3.01. The stock had a trading volume of 19,920 shares, compared to its average volume of 81,045. BioCardia has a 1 year low of $2.62 and a 1 year high of $43.17. The business’s 50 day moving average is $4.86 and its two-hundred day moving average is $6.50.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($1.35) earnings per share (EPS) for the quarter. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,208.76%. The firm had revenue of $0.06 million during the quarter. During the same quarter last year, the firm posted ($2.55) earnings per share. On average, equities analysts expect that BioCardia will post -6.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of BioCardia in a research report on Wednesday, May 29th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.